Overview

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

Status:
Active, not recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of NI-03.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kangen Pharmaceuticals, Inc
Stason Pharmaceuticals, Inc.